What type of study is this?

October 5, 2025Neuro-OncologyOpen Access

Ep08.02 the Clinical Outcome of Bevacizumab for Recurrent High-Grade Gliomas: A Polish Single Center Experience

View Full Paper

Ask AI

Bookmark

Authors

MNM. NawrockiNational Institute of Oncology ENElżbieta NowickaThe Maria Sklodowska-Curie National Research Institute of Oncology MZMarzena ZielińskaWroclaw Medical University

Discussion

Member takes

Implication

Retrospective analysis reveals progression-free survival and overall survival outcomes in high-grade gliomas, indicating bevacizumab may be a salvage option.

Key Points

Bevacizumab offers progression-free survival of 7.4 months and overall survival of 11.1 months for recurrent high-grade gliomas, emphasizing its potential as salvage therapy.
In a cohort of 15 patients, 60% were female, and 46.7% had glioblastoma as the histo-pathological diagnosis, highlighting gender and diagnosis diversity.
Adverse effects occurred in 20% of cases, with significant issues including hypertension and pulmonary embolism, indicating careful monitoring is essential.
No significant differences in survival were found across age, histopathology, or gender, suggesting bevacizumab effectiveness might be consistent among diverse patient groups.

Cite This Study

Nawrocki et al. (2025) studied this question.

synapsesocial.com/papers/68e24e59d6d66a53c2472f8a https://doi.org/10.1093/neuonc/noaf193.596

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals progression-free survival and overall survival outcomes in high-grade gliomas, indicating bevacizumab may be a salvage option.

Ep08.02 the Clinical Outcome of Bevacizumab for Recurrent High-Grade Gliomas: A Polish Single Center Experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Ep08.02 the Clinical Outcome of Bevacizumab for Recurrent High-Grade Gliomas: A Polish Single Center Experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider